Quantcast
Last updated on April 17, 2014 at 14:48 EDT

Latest Vaginal bleeding Stories

2012-03-12 08:05:00

PARSIPPANY, N.J., March 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya® (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical...

2012-01-18 20:02:50

Abnormal bleeding can be an early warning sign of cervical cancer and should not be ignored, said a gynecologic oncologist from Baylor College of Medicine. "January marks National Cervical Cancer Awareness Month and is a great time for women of all ages to be aware of common symptoms and early warning signs of the disease," said Dr. M. Yvette Williams-Brown, assistant professor of obstetrics and gynecology at BCM. "All women should know what constitutes abnormal bleeding." When caught...

2011-09-30 16:45:00

Oryzon announced today the positive outcome of its multicentric clinical trial for its new diagnostic test for the early detection of endometrial cancer. GynEC®-DX uses a gene-expression fingerprint to diagnose this cancer on uterine aspirates. The product has been developed in collaboration with Reig-Jofré Laboratories. The clinical trial has been performed in 16 Spanish hospitals and shows a reliability of 97%. The company will launch a second product in Spain and Portugal for...

2011-05-19 14:22:28

Published in the International Journal of Gynecology & Obstetrics Abnormal uterine bleeding (AUB) in women of reproductive age may be due to a wide range of disorders or pathologies. Until now, there has been no universally accepted method for classifying such patients, which has impeded basic science and clinical investigation, as well as the practical, rational, and consistent application of medical and surgical therapy. As the result of a stringent 5-year review process, a...

2011-05-02 05:45:00

PARSIPPANY, N.J., May 2, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. commercial launch of Generess(TM) Fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods. (Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO) Generess Fe...

2011-04-14 17:37:00

MISSISSAUGA, Ontario, April 14, 2011 /PRNewswire/ -- Theramed Corporation ("Theramed") announces that it has obtained the exclusive distribution rights in Canada for the EBB® Complete Tamponade System and the JETTY® Vaginal Repair Balloon, two newly developed medical devices used to advance the practice of obstetrics, from Glenveigh International, LLC ("Glenveigh"). [Both] medical device products have been approved for sale by Health Canada, and Theramed...

2011-04-06 06:35:00

ANDOVER, Mass., April 6, 2011 /PRNewswire/ -- Smith & Nephew's (NYSE: SNN; LSE: SN) Endoscopy Division today announced that its TRUCLEAR(TM) System, an operative hysteroscopy device for the removal of intrauterine polyps and fibroids, has surpassed the 30,000 procedure milestone. The TRUCLEAR System is a first-of-its kind device that pairs the visualization capabilities of a hysteroscope with minimally invasive tissue removal capabilities, allowing a fast and thorough capture and...

2011-01-07 06:00:00

BEDFORD, Mass., Jan. 7, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN...

2010-05-20 07:45:00

PRINCETON, N.J., May 20 /PRNewswire/ -- Novo Nordisk Inc. announced today that Vagifem® (estradiol vaginal tablets) 10 mcg will become the only available formulation of Vagifem® in the U.S., in line with medical recommendations for women to use the lowest effective estrogen dose to treat the symptoms of atrophic vaginitis due to menopause. The company will discontinue the sale of Vagifem® 25 mcg tablets in the U.S. on July 30, 2010....

2009-12-02 08:00:00

PRINCETON, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Novo Nordisk said today that the U.S. Food and Drug Administration (FDA) has approved a 10 mcg dose formulation of Vagifem® (estradiol vaginal tablets) for the treatment of atrophic vaginitis due to menopause - a condition experienced by up to 75 percent of postmenopausal women. This approval makes Vagifem® 10 mcg the lowest local estrogen therapy (LET) dose commercially available in the U.S. It will be...